Holen Sie sich die Stockscreener-App
330.34
3.60%
11.49
Handel nachbörslich:
320.05
-10.29
-3.11%
Schlusskurs vom Vortag:
$318.85
Offen:
$320.1
24-Stunden-Volumen:
1.25M
Relative Volume:
0.93
Marktkapitalisierung:
$43.81B
Einnahmen:
$3.71B
Nettoeinkommen (Verlust:
$313.75M
KGV:
146.36
EPS:
2.2571
Netto-Cashflow:
$465.38M
1W Leistung:
+4.51%
1M Leistung:
+3.02%
6M Leistung:
-26.92%
1J Leistung:
+40.13%
1-Tages-Spanne:
$320.10
$335.58
1-Wochen-Bereich:
$315.89
$335.58
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam (NASDAQ: ALNY) sets 2026 virtual meeting, board elections and pay vote - Stock Titan
[144] ALNYLAM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Porphyria Treatment Market to Reach US$ 358.64 Million by 2032 - openpr.com
Alnylam announces proposed offering of $500M convertible senior notes - msn.com
Perpetual Ltd Invests $2 Million in Alnylam Pharmaceuticals, Inc. $ALNY - marketbeat.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aberdeen Group plc Has $52.83 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - marketbeat.com
10 Best Future Stocks to Buy for the Next 5 Years - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26 - Insider Monkey
Alnylam CEO Greenstreet sells $2.23 million in stock - Investing.com
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26 - simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price - Sahm
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup - ChartMill
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Allspring Global Investments Holdings LLC - marketbeat.com
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now - insidermonkey.com
Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
Alnylam (ALNY) Highlights Breakthrough Vutrisiran Data at ACC An - GuruFocus
Alnylam's (ALNY) Zilebesiran Shows Promising Phase 2 Safety Data - GuruFocus
Alnylam presents cardiovascular data at ACC conference - Investing.com
Alnylam heart drug showed gains seen in patients 11 years younger - Stock Titan
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $360 - Moomoo
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy Recommendation - MSN
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
How Alnylam Pharmaceuticals Inc. (ALNY) Affects Rotational Strategy Timing - Stock Traders Daily
Assenagon Asset Management S.A. Sells 54,791 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The European Commission Approves Alnylam’s AMVUTTRA - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR FranchiseSlideshow (NASDAQ:ALNY) 2026-03-26 - Seeking Alpha
3 Stocks Trading Below Estimated Intrinsic Value By Up To 46.8% - simplywall.st
Vanguard amends 13G/A; reports 0 shares in Alnylam (ALNY) - Stock Titan
H.C. Wainwright reiterates Alnylam stock rating at buy, $510 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
SG Americas Securities LLC Buys 59,071 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies - Insider Monkey
Avidity Partners Management LP's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam (ALNY) jumps 6.7% as investors refocus on TTR franchise after company webinar - Quiver Quantitative
Chardan Capital Reaffirms "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
ALNY: HC Wainwright & Co. Reiterates Buy Rating with $510 Target - gurufocus.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at HC Wainwright - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - simplywall.st
Alnylam Ties AI Partnerships To ATTR CM Growth And Access Story - Yahoo Finance
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Narrow-Moat Alnylam's Growth Driven By Strong Demand For Amvuttra in ATTR-CM - Morningstar
Immutrin raises $87M to advance drug for progressive heart disease - BioPharma Dive
Morgan Stanley reiterates Alnylam stock Equalweight rating at $360 - Investing.com
Alnylam Pharmaceuticals Touts AMVUTTRA ATTR-CM Momentum, Raises 2026 TTR Revenue Outlook - MarketBeat
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | EVP Chief R&D |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
21,097 |
| Greenstreet Yvonne | Chief Executive Officer |
Mar 04 '26 |
Sale |
323.08 |
2,933 |
947,581 |
95,695 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,468 |
797,351 |
61,805 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
34,297 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 05 '26 |
Sale |
323.98 |
658 |
213,177 |
20,569 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 04 '26 |
Sale |
323.08 |
633 |
204,508 |
21,227 |
0.25%
2.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):